Introduction

A major breakthrough in the fight against tuberculosis (TB) could be on the horizon, with new vaccines expected to become available from around 2029. According to an analysis by Gavi, the Global Vaccine Alliance, these next-generation TB vaccines could prevent up to 7.3 million deaths between 2030 and 2050 if countries can secure sufficient, affordable and predictable supplies.

Gavi said the new vaccines could become a major immunisation tool, particularly for adolescents and adults who remain vulnerable to TB. However, the alliance warned that funding, manufacturing capacity and global demand could determine how quickly the vaccines reach the countries that need them most.

New TB Vaccines Could Transform Disease Prevention

Tuberculosis remains one of the world's biggest infectious disease threats. According to the latest available World Health Organization (WHO) statistics cited by Gavi, TB caused an estimated 1.23 million deaths in 2024.

The only currently licensed TB vaccine is Bacille Calmette-Guerin, commonly known as BCG. Developed more than a century ago, BCG has an important role in protecting infants and young children from severe forms of tuberculosis.

However, its protection can decrease over time, leaving adolescents and adults without the same level of protection. This has created a significant gap in TB prevention.

Gavi believes new vaccine candidates designed to provide protection later in life could help address this challenge.

Potential To Save Millions Of Lives

Gavi's analysis suggests that promising new TB vaccines could avert as many as 7.3 million deaths from 2030 through 2050.

The potential impact could be particularly significant in low- and middle-income countries, where tuberculosis continues to place a heavy burden on healthcare systems and communities.

The vaccines could also produce substantial economic benefits. Gavi estimates that successful deployment could unlock up to $135 billion in economic benefits across low- and middle-income countries by 2050.

Why Vaccine Supply Could Become A Major Challenge

Despite the promising outlook, Gavi has warned that developing an effective vaccine is only one part of the challenge. Ensuring that enough doses are manufactured and delivered at affordable prices could prove equally important.

Sania Nishtar, head of Gavi, described the new TB vaccines as having the potential to become the "next blockbuster immunisation tool." She stressed, however, that their full potential would depend on sufficient, predictable and affordable supplies for countries with the highest disease burden.

Uncertainty over future vaccine demand could also create problems. If manufacturers are unsure whether countries will purchase large numbers of doses, they may hesitate to invest in additional production capacity.

Funding And Financing Risks

Gavi identified inadequate global and domestic financing as another potential obstacle.

Even after regulatory approvals, countries will need adequate resources to purchase and distribute the vaccines. Limited healthcare budgets could delay adoption, particularly in nations already dealing with multiple infectious diseases and competing public-health priorities.

Without predictable financing, manufacturers could face uncertain demand, potentially slowing investments needed to scale production.

Gavi Plans Early Preparation For Vaccine Rollout

Gavi said it is already working with partners to prepare for the potential arrival of new TB vaccines.

The organisation plans to focus on several areas, including securing adequate vaccine supplies, supporting affordable access and encouraging countries to incorporate vaccination into routine immunisation programmes.

Gavi also said it wants to encourage a competitive and geographically diverse pipeline of new TB vaccine candidates. A broader manufacturer base could reduce supply risks and help countries access vaccines at competitive prices.

BCG Vaccine Still Remains Important

The potential arrival of new TB vaccines does not make the BCG vaccine irrelevant. BCG continues to play an important role in protecting young children against severe forms of tuberculosis.

The key difference is that newer vaccine candidates could potentially extend meaningful protection to older age groups, particularly adolescents and adults.

If successful, this could strengthen global TB prevention strategies by addressing a major limitation of the existing vaccination approach.

Economic Impact Could Extend Beyond Healthcare

Preventing millions of TB cases and deaths could have consequences far beyond reducing pressure on hospitals.

Tuberculosis can affect people's ability to work, study and support their families. A successful vaccination programme could therefore reduce productivity losses and healthcare costs while improving economic participation.

Gavi's estimate of up to $135 billion in economic benefits highlights the potential value of investing in TB vaccines, particularly across low- and middle-income economies.

Key Highlights

• New TB vaccines could become available from around 2029.
• Gavi estimates they could avert up to 7.3 million deaths between 2030 and 2050.
• TB caused an estimated 1.23 million deaths worldwide in 2024.
• BCG is currently the only licensed vaccine against tuberculosis.
• BCG is effective against severe TB in infants and young children, but its protection wanes.
• New vaccine candidates are being developed with adolescents and adults in mind.
• Gavi estimates potential economic benefits of up to $135 billion across low- and middle-income countries by 2050.
• Insufficient funding and manufacturing capacity could slow global vaccine access.
• Predictable and affordable supply will be critical for countries with high TB burdens.
• Gavi is working with partners ahead of potential regulatory approvals to prepare for vaccine rollout.

Professional Disclaimer & Third-Party Reference

This article is based on information attributed to Gavi, the Global Vaccine Alliance, and publicly available tuberculosis data referenced from the World Health Organization and syndicated third-party news reports. Figures, projections and vaccine-development timelines are subject to change as clinical trials, regulatory reviews, financing decisions and manufacturing plans progress. This article is intended for informational purposes only and should not be considered medical advice.

Conclusion

The development of new tuberculosis vaccines could mark a major turning point in the global fight against one of the world's deadliest infectious diseases. The possibility of preventing millions of deaths and generating significant economic benefits makes the technology highly promising. However, the ultimate impact will depend on whether governments, manufacturers and global health organisations can ensure affordable, reliable and widespread access once the vaccines are approved.

Follow the latest developments in TB vaccine research, global health and vaccine access to stay informed about this potentially transformative breakthrough.